Zhu [13] and colleagues revealed that the clinical benefit was tightly associated with pre-existing immunity (CD274 expression, T–effector signature, and intratumoral CD8+ T cells density) in patients with HCC when treated with atezolizumab (anti-PD-L1) combined with bevacizumab. This evidence concerns the gene CD8A and hepatocellular carcinoma.